PDGFRB and soft tissue sarcoma: Pazopanib, a PDGFRα and PDGFRβ/ VEGFR/ c-kit-targeting tyrosine kinase inhibitor [13], has been approved by Food and Drug Administration (FDA) for soft tissue sarcoma and renal cell carcinoma [36, 37].